- Method for synthesizing chiral amine compound
-
The present invention provides a method for synthesizing a chiral amine compound. The method comprises the following steps: (1) reacting a compound of formula I with t-butylsulfonamide in the presenceof a catalyst to obtain a compound having a structure represented by formula II; 2) reacting the compound of the formula II in a hydrogen atmosphere in the presence of an iridium catalyst and a ligand to obtain a compound of formula III; and (3) carrying out a t-butylsulfonyl group removal reaction on the compound of the formula III to obtain the chiral amine compound. The method constructs the structure of sulfonamide by a keto carbonylgroup, and synthesizes the chiral amine compound with the aralkylamine structure by an asymmetric catalytic hydrogenation reaction of the sulfonamide structure, the ee value is generally 80% or above, the highest ee value is 99% or above, the yield of each step reaction can reach 90% or above, and the total yield is high.
- -
-
Paragraph 0064; 0071-0073; 0126-0128
(2019/10/01)
-
- A JAK/STAT3 phosphorylation inhibitor and its preparation method and use thereof
-
The invention provides a JAK/STAT3 phosphorylation inhibitor as well as a preparation method and application thereof. The structural formula of the JAK/STAT3 phosphorylation inhibitor is as shown in a formula I, wherein X is selected from S or O; Y and Z
- -
-
Paragraph 0050
(2017/06/02)
-
- New quinoline NK3 receptor antagonists with CNS activity
-
Lead optimisation starting from the previously reported selective quinoline NK3 receptor antagonists talnetant 2 (SB-223412) and 3 (SB-222200) led to the identification of 3-aminoquinoline NK3 antagonist 10 (GSK172981) with excellent CNS penetration. Investigation of a structurally related series of sulfonamides with reduced lipophilicity led to the discovery of 20 (GSK256471). Both 10 and 20 are high affinity, potent NK3 receptor antagonists which despite having different degrees of CNS penetration produced excellent NK3 receptor occupancy in an ex vivo binding study in gerbil cortex.
- Smith, Paul W.,Wyman, Paul A.,Lovell, Peter,Goodacre, Caroline,Serafinowska, Halina T.,Vong, Antonio,Harrington, Frank,Flynn, Sean,Bradley, Daniel M.,Porter, Rod,Coggon, Sara,Murkitt, Graham,Searle, Kirsten,Thomas, David R.,Watson, Jeannette M.,Martin, William,Wu, Zining,Dawson, Lee A.
-
scheme or table
p. 837 - 840
(2009/09/06)
-
- Orally Bioavailable Caffeic Acid Related Anticancer Drugs
-
The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.
- -
-
Page/Page column 18
(2008/06/13)
-
- Substituted pteridines for the treatment of inflammatory diseases
-
The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as
- -
-
Page/Page column 6
(2010/11/08)
-
- THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS
-
Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).
- -
-
-
- 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
-
There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
- -
-
Page 136; 137
(2008/06/13)
-
- 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
-
There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
- -
-
-
- Influence of bulky substituents on histamine H3 receptor agonist/antagonist properties
-
Novel derivatives of 3-(1H-imidazol-4-yl)propanol were designed on the basis of lead compounds belonging to the carbamate or ether series possessing (partial) agonist properties on screening assays of the histamine H3 receptor. One pair of enantiomers in the series of α-methyl-branched chiral carbamates was stereoselectively prepared in high optical yields. Enantiomeric purity was checked by Mosher amide derivatives of precursors and capillary electrophoresis of the final compounds with trimethyl-β-cyclodextrin as chiral selector, and was determined to be ≥95%. The novel compounds were investigated in various histamine H3 receptor assays in vitro and in vivo. Some compounds displayed partial agonist activity on synaptosomes of rat brain cortex, whereas others exhibited antagonist properties only. Selected compounds were investigated in [125I]iodoproxyfan binding studies on the human histamine H3 receptor and showed high affinity in the nanomolar concentration range. Under in vivo conditions after oral administration to mice, some of the compounds exhibited partial or full agonist activity in the brain at low dosages. The (S)-enantiomer of one pair of chiral carbamates (9) proved to be the eutomer; thus, the (S)-enantiomer was selected for further pharmacological studies. In a peripheral in vivo test model in rats, measuring the level of inhibition of capsaicin-induced plasma extravasation, (S)-9 again proved its high oral agonist potency with full intrinsic activity (ED50 values of 0.07-0.1 mg/kg depending on tissue).
- Sasse, Astrid,Ligneau, Xavier,Rouleau, Agnès,Elz, Sigurd,Ganellin, C. Robin,Arrang, Jean-Michel,Schwartz, Jean-Charles,Schunack, Walter,Stark, Holger
-
p. 4000 - 4010
(2007/10/03)
-
- Branched alkylamino derivatives of thiazole, processes for preparing them and pharmaceutical compositions containing them
-
The invention relates to the derivatives of formula I: STR1 in which R1 represents a phenyl or naphthyl radical (optionally substituted), R2 represents a hydrogen or halogen atom or an alkyl, hydroxymethyl or formyl radical, R3
- -
-
-
- Hypoglycemic α cycloalkylphenylmethyl, furanalkyl, and thiophenealkyl lactamimides
-
A series of α cycloalkylphenylmethyl lactamimides and a series of furan and thiophenealkyl lactamimides were prepared for biological evaluation as an extension of earlier findings of hypoglycemic activity in lactamimides. Several compounds produced pronouced hypoglycemia after oral administration to fasted, glucose primed rats.
- Grisar,Claxton,Wiech
-
p. 365 - 369
(2007/10/04)
-